APA (7th ed.) Citation

Miles, D., Chan, A., Dirix, L., Cortés, J., Pivot, X., Tomczak, P., . . . Romieu, G. (2010). Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. American Society of Clinical Oncology.

Chicago Style (17th ed.) Citation

Miles, D., et al. Phase III Study of Bevacizumab Plus Docetaxel Compared with Placebo Plus Docetaxel for the First-line Treatment of Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer. American Society of Clinical Oncology, 2010.

MLA (9th ed.) Citation

Miles, D., et al. Phase III Study of Bevacizumab Plus Docetaxel Compared with Placebo Plus Docetaxel for the First-line Treatment of Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer. American Society of Clinical Oncology, 2010.